Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q4J6C6

UPID:
PPCEL_HUMAN

ALTERNATIVE NAMES:
Prolylendopeptidase-like

ALTERNATIVE UPACC:
Q4J6C6; A7E2X6; D6W5A3; O43163; Q4J6C3; Q4J6C4; Q4ZG39; Q6ZMW7; Q96DW7

BACKGROUND:
The Prolyl endopeptidase-like protein, with alternative names such as Prolylendopeptidase-like, is instrumental in maintaining cellular function through its serine peptidase activity and regulation of membrane-cytoplasm recycling. Its precise role in peptide cleavage and synaptic function remains a subject of scientific inquiry.

THERAPEUTIC SIGNIFICANCE:
Its association with diseases such as Hypotonia-cystinuria syndrome and congenital Myasthenic syndrome, 22, underscores the therapeutic significance of Prolyl endopeptidase-like. Exploring its function could lead to groundbreaking therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.